In patients with heterozygous familial hypercholesterolemia already taking maximally tolerated lipid-lowering medication, resmetirom lowered LDL, triglycerides, apolipoprotein B and lipoprotein(a) levels vs. placebo, researchers reported.“Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant genetic disorder, with an estimated prevalence of approximately one in 200 to
Great to have more therapies for FH